Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mainz Biomed N.V. - Ordinary Shares
(NQ:
MYNZ
)
0.6090
-0.0095 (-1.54%)
Streaming Delayed Price
Updated: 12:45 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mainz Biomed N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 17, 2024
The final day of trading this week is here and we have the biggest pre-market stock movers worth watching on Friday morning!
Via
InvestorPlace
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16, 2024
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,...
Via
Benzinga
mRNA Is Promising A Breakthrough In Fighting Cancer
April 29, 2024
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it...
Via
Benzinga
Exposures
COVID-19
The Latest Analyst Ratings for Mainz Biomed
November 20, 2023
Via
Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:
Via
Benzinga
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
April 09, 2024
MYNZ stock results show that Mainz Biomed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
April 02, 2024
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic.
Via
Benzinga
Exposures
COVID-19
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
February 28, 2024
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track...
Via
Benzinga
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
February 07, 2024
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine...
Via
Benzinga
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 02, 2024
--News Direct--
Via
News Direct
Topics
Death
Exposures
Death
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
February 01, 2024
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a...
Via
Benzinga
Exposures
COVID-19
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
February 01, 2024
The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the...
Via
Benzinga
Topics
Death
Exposures
Death
2024 Marks a New Era Of Pharmaceutical Innovation
January 09, 2024
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned...
Via
Benzinga
Exposures
COVID-19
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
December 29, 2023
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc.
Via
Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
December 19, 2023
Via
Benzinga
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 05, 2023
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 05, 2023
Via
Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
December 05, 2023
Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
November 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 14, 2023
Via
Benzinga
Crude Oil Gains Over 1%; US Budget Deficit Narrows For October
November 13, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 50 points on Monday. The Dow traded up 0.16% to 34,337.33 while the NASDAQ fell 0.11% to 13,783.41. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 13, 2023
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 13, 2023
Via
Benzinga
Why Mainz Biomed (MYNZ) Stock Is Getting Hammered
November 13, 2023
Mainz Biomed NV (NASDAQ: MYNZ) shares are trading lower by 46% to $1.21 during Monday's session has entered a securities purchase agreement with institutional investors to raise $5 million through a
Via
Benzinga
Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher
November 13, 2023
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.33% to 34,397 while the NASDAQ fell 0.06% to 13,790. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Fall; Tyson Foods Posts Upbeat Earnings
November 13, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.08% to 34,254.53 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Mainz Biomed Partners With Liquid Biosciences In Exclusive Relationship To Harness The Power Of Artificial Intelligence (AI) To Develop Next-Generation Colorectal Screening Test
November 13, 2023
The integration of Artificial Intelligence (AI) in biotechnology is rapidly gaining momentum, revolutionizing the field of life sciences. AI technologies, such as machine learning and deep learning...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Mainz Biomed’s (NASDAQ: MYNZ) ColoFuture Study Reveals “Groundbreaking Results”: ColoAlert® Raises The Bar For Colorectal Cancer Detection
November 08, 2023
--News Direct--
Via
News Direct
Topics
Death
Exposures
Death
AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test
November 07, 2023
Mainz Biomed N.V. (NASDAQ: MYNZ) inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.